Cancer Biology & Genetics Program
The Luis Parada Lab
The Parada lab uses genetically engineered mouse models to recapitulate and study human disease. These mouse strains are used to understand the natural history of tumors of the nervous system, including glioblastoma multiforme (GBM), malignant peripheral nerve sheath tumors (MPNST), neurofibromas, and other diseases associated with neurofibromatosis (NF1). We seek to develop mouse cancer models based on concrete hypotheses and to rapidly transfer findings for validation in human cancer samples.
Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy. 2022. Xie XP, Laks DR, Sun D, Ganbold M, Wang Z, Pedraza AM, Bale T, Tabar V, Brennan C, Zhou X, Parada LF. 2022, Dev Cell, PMCID: PMC8820651.
Stem-like cells drive NF1-associated MPNST functional heterogeneity and relapse after chemotherapy. 2021. Sun D, Xie X, Wang Z, Sait S, Iyer S, Chen Y, Brown R, Laks D, Chipman M, and Parada L. 2021, Cell Stem Cell, PMCID: PMC8349880
High resolution mouse subventricular zone stem cell niche transcriptome reveals features of lineage, anatomy, and aging. Xie XP, Laks DR, Sun D, Poran A, Laughney AM, Wang Z, Sam J, Belenguer G, Fariñas I, Elemento O, Zhou X, Parada LF., 2020. Proceedings of the National Academy of Sciences. Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31448-31458. doi: 10.1073/pnas.2014389117. Epub 2020 Nov 23.
Cell Lineage-Based Stratification for Glioblastoma. Wang Z, Sun D, Chen YJ, Xie X, Shi Y, Tabar V, Brennan CW, Bale TA, Jayewickreme CD, Laks DR, Alcantara Llaguno S, Parada LF. Cancer Cell. 2020 Sep 14;38(3):366-379.e8. doi: 10.1016/j.ccell.2020.06.003. Epub 2020 Jul 9. PMID: 32649888; PMCID: PMC7494533.
Luis F. Parada, PhD
Director, Brain Tumor Center; Albert C. Foster Chair; American Cancer Society Research Professor; Professor, Cell and Developmental Biology Program, Weill Cornell Graduate School of Medical Sciences
- Developmental biologist Luis F. Parada uses genetically engineered mouse models to study neurofibromatosis, brain tumors, cancer stem cells, and tumor progression.
- PhD, Massachusetts Institute of Technology
- [email protected]
- Email Address
- 646-888-2055 (Assistant to Dr. Parada)
- Office Phone
- MD, National Yang Ming University
- MS, National Yang Ming University
- Masters in Biophysics from the National University of Mongolia
- Masters in Biomedical Informatics from New York University
- Member, National Academy of Science (2011)
- Fellow of American Association for the Advancement of Science (2009)
- Member, National Academy of Medicine- Former Institute of Medicine (2007)
- The Academy of Medicine, Engineering and Sciences of Texas (TAMEST) (2007)
- Member, American Academy of Arts and Sciences (2007)
- Member, Dana Alliance for Brain Initiatives (2003)
- Professor, American Cancer Society Research (2002)
To learn more about available postdoctoral opportunities, please visit our Career Center
The Luis F. Parada laboratory currently has a position open for a postdoctoral research fellow.
Get in Touch
Lab Head Email
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Luis F. Parada discloses the following relationships and financial interests:
Thermo Fisher Scientific, Inc
Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].